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Abstract
Purpose
To evaluate changes in colour vision following intravitreal injection of Dexamethasone
implant (Ozurdex) in patients with diabetic macular oedema (DMO). Both red-green (RG)
and yellow-blue (YB) chromatic sensitivity were assessed using the Colour Assessment &
Diagnosis (CAD) test which isolates the use of colour signals and provides age-corrected,
statistical limits for normal trichromats. To determine whether colour changes and visual
acuity (VA) post-treatment relate to central sub-field retinal thickness (CST).
Methods
Fourteen patients with DMO who were undergoing treatment with Ozurdex were recruited
for this study. RG and YB colour thresholds were measured using the CAD test, best cor-
rected visual acuity was assessed using the ETDRS chart and CST was measured using
spectral domain optical coherence tomography (SD-OCT). All tests were performed monoc-
ularly at baseline and 24 weeks post injection.
Results
All patients (n = 14 eyes), had significant loss of RG and YB chromatic sensitivity at baseline
(p<0.05). The mean age was 56 ± 9.5 years. The age specific, monocular, upper normal lim-
its for a 56 year old subject are 2.66 for RG and 2.85 for YB. In this study, the measured, pre
injection thresholds (mean±SD) were 22.6 ± 11.3 for RG and 16.2 ± 3.76 for YB. There was
significant improvement in RG threshold post injection (i.e., 19.2 ± 10.8 (p<0.05)). No signifi-
cant changes were found in the YB thresholds with corresponding mean and range values
of: 15.8 ± 4.6 (p = 0.23). CST pre-treatment was 542 ±135 μm. After treatment and by week
24 the CST values decreased to 435 ±127 μm.
Conclusions
RG colour thresholds provide a sensitive measure of functional change in diabetic subjects
with macular oedema. The YB system is damaged severely in the DMO patients studied
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and shows little or no recovery post treatment. The improvement in VA and particularly in
RG colour vision correlate well with the measured decrease in CST. The results suggest
that the improvement in the RG chromatic sensitivity can provide a useful biomarker for
monitoring the efficacy of treatment in DMO.
Introduction
Diabetic macular oedema (DMO) affects 20% of patients with DR [1] and can cause vision loss
independent of the grade of retinopathy.
Inflammation plays an important role in the pathophysiology of DMO and is mediated
through the expression of prostaglandins, leukotrienes and VEGF [2]. As a result, steroids can
play a vital role in decreasing intracellular and extracellular oedema through inhibition of
these factors by suppression of macrophage activity, vasoconstrictive effect, and reduction of
lymphokine production [3].
The standard care for DMO has evolved over several years and relies mostly on the control
of the systemic condition: diabetes, blood pressure and lipid management. Macular laser
photocoagulation was the mainstay of treatment for over 30 years [4]. More recently anti-
VEGF has been introduced for use in the treatment of DMO. Steroids can also be useful in the
treatment of DMO by blocking the production of VEGF and other inflammatory mediators
[5–8]. The use of steroids is, however, associated with raised intraocular pressure (IOP) in up
to 50% of patients and cataract formation in 40% of the injected eyes [9]. Similar to anti-
VEGF drugs such as ranibizumab, the effect is short-lived and patients require frequent injec-
tions with higher cumulative risks of side effects.
Sustained release corticosteroids have been developed with the aim of offering longer last-
ing effects that reduce the need for frequent intravitreal injections. The dexamethasone intravi-
treal implant—Ozurdex (Allergan Inc., Irvine, CA, USA) is a sustained-release biodegradable
implant made of polyacticglycolic acid matrix, containing dexamethasone that is injected into
the vitreous through the pars plana using a customized applicator. It releases 700mg dexa-
methasone slowly into the posterior segment. This treatment has been shown to be effective in
chronic DMO and DMO which is resistant to anti-VEGF treatment [10, 11].).
The OCTOME study study [12] was designed to evaluated the morphological and func-
tional changes following treatment with Ozurdex in patients with MO secondary to DR and
vein occlusion. The The OCTOME report 1 confirmed that the therapeutic effect of Ozurdex
lasts up to 36 weeks in terms of improvement of visual function and macular thickness in
patients with MO. It also concluded that if re-treatment is needed, re-injection of Ozurdex at
20 weeks is appropriate and ensures effectiveness with least side-effects [12].
Although measurement of retinal thickness using OCT scans is a useful tool to monitor the
response to treatment, it cannot substitute the measurement of VA and both OCT and VA have
a place in the monitoring of diabetic changes. It is, however, well established that VA does not
always correlate well with clinical severity of MO [13]. Other visual functions such as functional
contrast sensitivity, colour vision (CV) and rapid flicker sensitivity may provide a better under-
standing of the effect of Ozurdex on MO. In this study we measured and compared changes in
RG and YB colour thresholds with the corresponding changes in VA and CST to quantify the
effects of Ozurdex treatment on other aspects of vision. The patients investigated in this explor-
atory study represent only a small subgroup recruited for the larger OCTOME study [12].
Our specific aim was to measure and compare changes in RG and YB thresholds using the
Colour Assessment and Diagnosis (CAD) test [14] “Fig 1” in patients with DMO pre- and
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post-Ozurdex (Dexamethasone implant) intravitreal injection. The study assessed the severity
of RG and YB colour loss before treatment and established whether treatment with Ozurdex
led to any significant changes in colour vision. Of particular interest is to establish whether
selective changes in RG and / or YB colour vision correlate with reduction in CST and whether
such changes can be used to evaluate the efficacy of Ozurdex treatment in DMO.
Methods
Subjects were recruited from the Ophthalmology outpatient department of King’s College
Hospital NHS Foundation Trust, London. The study was approved by the Research and Ethics
Committees of King’s College Hospital and City, University of London. All participants gave
written informed consent and the study adhered to the principles of the Declaration of
Helsinki.
Subjects
This study examined 14 diabetic patients with DMO. The participants represent a subset
recruited from the 24 diabetic patients examined in the OCTOME study which was an inter-
ventional, prospective and exploratory study [12]. The remaining 10 diabetic patients, not
included in this study, had either age-related decline in cognitive ability or very poor visual
acuity. As a result they were unable to complete the one minute learning stage with 100% accu-
racy, a task which does not rely on the use of CV. During the learning task, the CAD stimulus
“Fig 1” is defined by both colour and luminance contrast and is always seen by both normal
trichromats and dichromats. 100% performance in the learning task is recommended to
ensure that the patients understand the requirements of the visual task and can use the keypad
response buttons “Fig 1” without error.
All participants had to meet the criteria listed below:
Fig 1. Screen dumps of CAD test stimuli and template plot. Section A shows stimulus colours that isolate the RG
and YB axes. The mean threshold ellipse measured with respect to a daylight backgroud (CIE- (x, y): 0.305, 0.323) is
also shown together with the RG and YB axes and the bespoke keypad employed to record the subject’s responses.
Section B shows the standard CAD units for RG and YB colour vision (i.e., the ‘red’ and ‘blue’ arrows) which equal the
minor and major axis of the mean threshold ellipse measured for 330 young, healthy normal trichromats [14]. The
coloured sysmbols show typical thresholds measured in a subject with normal trichromatic colour vision. Section B,
the grey shaded area shows the range of variation expected for young normal trichromats, the innermost and
outermost ellipses corresponding to 2.5% and 97.5% confidence limits for normal population, respectively [18]. The
dotted black ellipse represents the mean threshold values which define the young standard normal CAD observer. The
corresponding mean thresholds are normalised to unity and all other CAD thresholds are expressed in these standard
normal units (SNU). Upper normal CAD threshold limits have also been measured as a function of age in a separate
study [20]. The smallest colour thresholds correspond to ~ 20 years of age and are followed by a gradual, linear
increase of ~ 1% per year for RG and ~ 1.6% for YB, over the remaining life span. Each patient’s thresholds measured
in this study were compared against the upper normal threshold limits for the corresponding age [20].
https://doi.org/10.1371/journal.pone.0199693.g001
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• The best corrected visual acuity (BCVA) in the study eye had to be in the range 37 and 68
ETDRS Letters, this level of performance is equal to 1.26 and 0.64 LogMAR acuity,
respectively.
• Patients were excluded if they had any other eye disease which could mask or contribute to
MO, or any ocular condition in the study eye that would prevent a 15-letter improvement in
visual acuity (e.g., severe macular ischemia, extensive macular laser scarring or atrophy).
• Patients were also excluded if they had advanced glaucoma that was not controlled ade-
quately by drugs alone, or a history of IOP elevation in response to steroid treatment in
either eye that resulted in10mmHg increase in IOP from baseline with an absolute IOP
25mmHg, or required therapy with three or more anti-glaucoma medications.
• Patients were excluded if they had any systemic conditions that precluded trial entry such as
known uncontrolled systemic disease or current immunosuppressive disease, initiation of
medical therapy for diabetes, or a change from oral hypoglycaemic agents to insulin therapy
within 4 months before the screening visit and renal failure requiring haemodialysis or peri-
toneal dialysis within 6 months before screening visit.
Ophthalmic assessments
All patients were examined at baseline (week 1) and then subsequently at 24 weeks for this arm
of the OCTOME study. Monocular BCVA was measured using the standard ETDRS protocol
and scored as the total number of ETDRS letters read correctly. CST was measured using the
Spectralis SD-OCT (Heidelberg engineering GmbH, Heidelberg, Germany). CST measure-
ments are generated automatically and follow the 9th Early Treatment Diabetic Retinopathy
Study (ETDRS) subfields which are arranged in inner, intermediate and outer rings with radii
of 1mm, 2.22mm and 3.45 respectively. The average of all points within the inner circle is
defined as central sub-field thickness. Monocular RG and YB chromatic sensitivity was mea-
sured with the CAD test [14].
The CAD test (City Occupational Ltd., London, UK) measures colour thresholds along 16
directions, away from a ‘white’ background equivalent to daylight (D65). The measured thresh-
olds provide an accurate estimate of the severity of RG and YB colour vision loss. The CAD
results also classify the participant’s class of colour vision (i.e., normal trichromatic colour
vision, deutan-, protan-, tritan-like congenital deficiency or acquired deficiency).
The stimulus is generated with 30 bit resolution in the centre of a large uniform background
field on a visual display (NEC-spectraview PA241-W). The coloured stimulus is buried in
dynamic luminance contrast noise and subtends ~ 30 x 30 min arc at the eye “Fig 1” from a
recommended viewing distance of 1.4m. The test is based on background perturbation tech-
niques [15–18] developed to mask detection of luminance contrast and to isolate the use of col-
our signals [14, 19].
Patients with refractive errors wore their appropriate refractive correction for the corre-
sponding distance of 1.4 m. All patients viewed the visual display with the head / eye position
in line with the centre of the monitor. The test was carried out monocularly in the eye with the
best BCVA. The full CAD test takes about 3 minutes for YB and ~ 10 minutes for RG to
complete.
The initial validation of the CAD test and the statistical limits needed to describe RG and
YB colour sensitivity in young subjects with normal trichromatic colour vision are based on
RG and YB thresholds measured in 330 normal trichromats (Civil Aviation Authority (UK),
2009).
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Optical coherence tomography
OCT scans were carried out using the standard protocol on the Heidelberg Spectralis SD-OCT
(Heidelberg Engineering, Heidelberg, Germany) [21]. All scans were performed by two experi-
enced medical photographers.
All patients had the Ozurdex (Dexamethasone implant) intravitreal injection on week 1
(baseline). According to the protocol from OCTOME study some of the patients were eligible
for a second injection at the re-treatment window between week 16 and week 24.
Changes in the patient’s VA, RG and YB thresholds were compared against the correspond-
ing changes in CST.
Statistical analysis
The data were analysed using MS Excel (V.15.0) and SPSS programs (SPSS V.22.0, SPSS, Chi-
cago, IL, USA). Analysis was performed using t-tests to calculate p values and categorical vari-
ables were examined using Pearson’s r2 correlation. Differences in results were assumed
significant for p-values <0.05.
Results
Descriptive data
The study included 14 patients. Demographic and baseline characteristics are shown in Table 1.
Table 1. Demographic and baseline characteristics of the patients examined in this study.
Mean age (SD), years 56±9.23
Range, years 40–68
Gender, n (%)
Male, n (%) 12 (85.7)
Female, n (%) 2 (14.2)
Race, n (%)
Afrocaribbean 4 (28.6)
Asian 2 (14.3)
White 8 (57.1)
Grade of diabetic retinopathy, n (%)
Mild and moderate NPDR 6 (42.8)
Severe NPDR 3 (21.4)
Treated PDR 5 (35.7)
Smokers, n (%) 2 (14.3)
Mean HbA1C, n (SD) 7.8±1.39
8%, n (%) 6 (50)
>8%, n (%) 6 (50)
Hypertensives on treatment, n (%) 9 (64.3)
Previous glaucoma medications 0
Previous macular laser, n (%) 12 (85.7)
Mean number of laser treatments, n (SD) 2.2±1.6
Mean ETDRS letter score, n (SD) 59.71±9.20
<54 letters, n (%) 4 (28.6)
54 letters, n (%) 10 (71.4)
Abbreviations: ETDRS (early treatment diabetic retinopathy study); HbA1C (glycosylated haemoglobin); NPDR
(non-proliferative diabetic retinopathy); PDR (proliferative diabetic retinopathy)
https://doi.org/10.1371/journal.pone.0199693.t001
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Lens opacity
Lens yellowing and senile pupil miosis have been linked to age-related deterioration of CV
caused largely by significant reduction in retinal illuminance [22, 23]. The density of cataract
in the current study was graded using Lens Opacities Classification System III (LOCS III) [24]
“Table 1”. 12 patients had LOCS III gradingN1C1 and two patients were pseudophakic.
Change in RG and YB thresholds
The mean age of the 14 patients was 56 years (range, 40 to 68) and the age specific, monocular,
upper normal CAD limits for a 56 years old subject are 2.66 for RG and 2.85 for YB. In this
study, all the patients were outside the normal, age-matched, upper threshold limits [20]. The
RG pre-injection threshold was 22.57 ±11.27 (range, 2.95 to 35.87) whilst the YB mean thresh-
old was 16.21 ± 3.76 (range, 15.18 to 18.19) “Fig 2”. It is important to note that the upper limit
of 18.19 CAD units was the highest possible chromatic displacement along the tritanopic col-
our confusion line.
Significant improvements in RG thresholds post injection 19.18 ±10.84 (t (13) = 1.965,
p<0.05) were observed. Post injection the YB thresholds were only fractionally smaller with
reductions that failed to reach statistical significance (15.84 ± 4.60 (t (13) = 0.747, p = 0.23).
Only three patients showed significant improvement in their YB threshold “Table 2 and Fig 3”.
The results shown in “Fig 3” are of interest since 11 out of the 14 patients have severe loss of
YB colour vision with thresholds that are limited only by the visual display. The damage to the
YB system is therefore extensive and these subjects show little or no recovery of YB sensitivity
post treatment. In contrast, 11 out the 14 patients studied have RG thresholds that are well
below the display limits and show significant recovery post treatment.
Individual changes in VA, CST and colour thresholds
The benefits of Ozurdex treatment is calculated by measuring the patient-specific changes in
RG and YB colour thresholds, VA and CST at week 24, post treatment. The data for RG and
YB colour vision are shown in “Fig 4”. A negative change represents improvement. There was
little or no improvement in YB colour vision in all but one patient post treatment. The YB col-
our system is, however, heavily damaged in this patient group with thresholds limited only by
the visual display “Fig 3”. This is not the case for RG thresholds, VA and CST, all of which
show significant improvements in the majority of patients post treatment.
CST changes and corresponding correlations with colour vision and VA
The changes in RG colour vision are also compared for each subject against the corresponding
YB changes “Fig 5(A)”. The data show clearly that whilst the majority of patients show signifi-
cant improvement in RG thresholds, with one exception, the YB thresholds remain largely
unchanged post treatment. The results also demonstrate the importance of CST measurements
in patients with DMO. With the exception of the YB system which may be permanently dam-
aged in many of the patients examined in this study, the extent of recovery in both VA and RG
colour vision correlates well with differences in CST measurements “Fig 5C and 5D”. Percent-
age differences in RG thresholds exhibit the highest correlation with CST “Fig 5C”. Individual
patient data are also shown in Table 2. The number of patients who gained more than 5 or 15
letters by week 24 were 6 (43%) and 4 (28%), respectively. Three patients (21%) lost 2 letters or
less, with another patient losing 9 letters by week 24. The mean CST measured before treat-
ment with Ozurdex was 542 ±135 μm. Following treatment and by week 24 the mean CST was
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found to be 435 ±127 μm, a significant reduction consistent with the percentage improvements
in RG thresholds “Fig 5C”, (t (13) = 2.202, p<0.05).
Fig 2. CAD results before and after Ozurdex treatment in two subjects with diabetes (A- subject 11; B- subject 4).
Both subjects show significant improvement in chromatic sensitivity (i.e., smaller thresholds) post treatment. The grey,
dotted lines show the colour limits imposed by the phosphors of the display. Subject B was unable to detect YB colour
changes, even for the largest chromatic signals that are limited only by the phosphors of the display with no
improvement post treatment. The RG thresholds, on the other hand, show significant improvement post-treatment.
https://doi.org/10.1371/journal.pone.0199693.g002
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Discussion
This preliminary study examined changes in RG and YB chromatic sensitivity, VA and CST in
eyes undergoing intravitreal injection of dexamethasone implant (Ozurdex) as treatment for
Table 2. Change in RG and YB thresholds, visual acuity and CST.
Subject SNO R-G SNO Y-B BCVA ETDRS Letters (LogMAR) CST
Before After Change Before After Change Before After Change Before After Change
1 31.07 30.30 -0.77 18.15 18.10 -0.05 61 (0.48) 59 (0.52) -2 530 411 -119
2 19.46 22.99 3.53 18.16 18.08 -0.08 67 (0.36) 85 (0.00) 18 580 411 -169
3 12.61 15.93 3.32 18.10 18.07 -0.03 68 (0.34) 59 (0.52) -9 491 533 42
4 25.64 17.20 -8.44 18.17 17.71 -0.46 67 (0.36) 76 (0.18) 9 501 378 -123
5 34.45 34.58 0.13 18.18 18.18 0.00 40 (0.90) 39 (0.92) -1 422 518 96
6 7.78 9.63 1.85 13.58 16.95 3.37 58 (0.54) 64 (0.42) 6 572 603 31
7 28.58 22.54 -6.04 18.19 18.13 -0.06 52 (0.66) 71 (0.28) 19 685 692 7
8 11.96 8.95 -3.01 15.70 14.28 -1.42 67 (0.36) 73 (0.24) 6 585 385 -200
9 35.87 36.18 0.31 18.10 18.16 0.06 65 (0.40) 64 (0.42) -1 578 507 -71
10 30.51 17.72 -12.79 18.18 18.15 -0.03 49 (0.72) 69 (0.32) 20 573 299 -274
11 11.14 8.84 -2.30 11.72 5.99 -5.73 58 (0.54) 70 (0.30) 12 390 448 58
12 35.02 31.82 -3.20 18.12 18.05 -0.07 68 (0.34) 77 (0.16) 9 315 235 -80
13 29.03 9.57 -19.46 17.52 17.43 -0.09 48 (0.74) 73 (0.24) 25 881 268 -613
14 2.95 2.35 -0.60 5.18 4.57 -0.61 68 (0.34) 75 (0.20) 7 485 414 -71
https://doi.org/10.1371/journal.pone.0199693.t002
Fig 3. RG and YB thresholds. Shows thresholds measured before treatment in the 14 DMO patients, together with the
maximum chromatic saturations that can be produced on the visual display (i.e., the limits of colour saturation in CAD
units that can be generated on the visual display).
https://doi.org/10.1371/journal.pone.0199693.g003
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DMO. All patients showed loss of RG and YB chromatic sensitivity at recruitment with YB col-
our vision being most affected “Fig 3”. Recovery of YB colour vision post treatment “Figs 4
and 5A” is almost absent and this suggests significant damage to YB chromatic mechanisms in
all but one of the DMO patients. RG sensitivity, on the other hand, recovers well post treat-
ment “Fig 5A”. The differences in RG sensitivity between post and pre-treatment tests corre-
late well with the corresponding individual reduction in CST. This observation also holds true
for differences in VA, although higher correlation is observed with differences in RG thresh-
olds “Fig 5”.
All patients recruited in our study had chronic DMO, therefore they would have had previ-
ous treatments such as laser—focal or grid, intravitreal triamcinolone and anti-VEGF injec-
tions. Given the advanced level of damage to the retina, it was not unexpected to find
significant loss of colour vision in all patients with YB colour vision being almost absent in
some patients. Most of the patients examined had a degree of cataract which is a known associ-
ation with diabetes [25]. This can affect chromatic sensitivity when the ambient light level is
low causing an overall reduction in retinal illuminance. Although ocular opacities may have
contributed in part to the massive loss of YB chromatic sensitivity, the absence of significant
recovery in YB thresholds in all but one of the patients “Fig 5A” suggests the presence of signif-
icant permanent damage to the YB system. The RG system shows greater resilience in DMO
with significant post treatment recovery which correlates well with the reduction in retinal
thickness “Fig 5C”.
VA also improves significantly post treatment, but the correlation with percentage differ-
ences in CST is highest for RG colour vision “Fig 5C and 5D”.
In the related study-OCTOME [12], Ozurdex produced an improvement in visual acuity
with maximal gain achieved by 12 weeks. At 24 weeks post treatment, while the gain in visual
acuity started to regress, RG colour vision continued to exhibit significant improvement.
Fig 4. Changes in RG and YB colour thresholds following treatment with Ozurdex, plotted for each of the
patients examined. A ‘negative’ percentage change indicates an improvement. It shows little or no improvement in YB
colour vision, but a significant improvement in RG colour vision in the majority of patients.
https://doi.org/10.1371/journal.pone.0199693.g004
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Interestingly, the mean decrease in CST showed a similar trend with initial significant
improvement that was more evident by week 8, followed by smaller changes from week 16
onwards.
The data from this preliminary study suggest that changes in CST thickness correlate best
with differences in RG colour vision followed by VA. The results also suggest that the YB sys-
tem can be damaged permanently in DMO with little or no recovery post treatment.
Many previous studies have established that chromatic sensitivity is affected in diabetic reti-
nopathy [26–29]. The mechanisms by which colour vision is affected in DMO remain poorly
understood. Some explanations have been put forward to account for the observed losses, but
these have been questioned. Several studies [30–33] examined the events of vascular and
Fig 5. CST changes and corresponding correlations with colour vision and VA. Section A illustrates more clearly the absence of
significant changes in YB thresholds when compared to the improvements in RG colour vision. Sections B and C show how the percentage
decrease in CST correlates with the corresponding changes in YB (B) and RG (C) thresholds. Section D shows how changes in CST
correlate with the changes in LogMAR VA post treatment. A ‘negative’ change indicates an improvement in VA. The results suggest that
decreased CST values correlate well with improvement in RG colour vision (r2 = 0.43) and VA (r2 = 0.34). The YB system, on the other
hand, appears to be damaged more severely and shows negligible correlation with the corresponding CST changes (r2 = 0.05).
https://doi.org/10.1371/journal.pone.0199693.g005
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neuronal apoptosis that occur in DR as the prime cause of colour vision loss. These studies
above focused on the various mechanisms that are thought to cause retinal cell apoptosis (vas-
cular and neuronal retina). Exposure to oxidative stress and reduced growth factor signalling
have been identified as potential contributors to loss of colour vision. Hyperglycaemia can
induce oxidative stress leading to apoptotic signalling. Growth factor signalling is essential for
the survival of neurones, pericytes and endothelial cells. These studies demonstrated how dia-
betes impairs the trophic signals pathway leading to reduction in survival signals and hence
increased chances of apoptosis.
Barber at al., [34] also demonstrated that glutamate excitotoxicity can cause damage to the
neuronal retina and therefore contribute to both chronic and acute neurodegeneration.
Neuro-inflammation is also an important factor to be considered in the pathology of diabetic
retinopathy and subsequent colour vision defects. Some studies [35–37] have identified
increased levels of cytokines, especially vascular endothelial growth factor (VEGF), interleukin
(IL)-1 B, IL-6, IL-8 and tumour necrosis factor (TNF)-α in the vitreous of DMO patients and
patients with PDR.
The effect of circulating oxygen saturation on colour thresholds has also been investigated
[38]. Dean et al., examined 37 Type I diabetics with either mild or absent DR. An improvement
in colour thresholds was demonstrated in all subjects after breathing oxygen (100%). They
concluded that reduced oxygen saturation can lead to impaired colour vision which is likely to
be because photoreceptors are functioning at suboptimal oxygen levels. A similar study con-
ducted by Connolly et al., [39] showed that chromatic sensitivity was impaired in aircrew
when subjected to mild hypoxia as opposed to those under normoxic or hyperoxic conditions.
A majority of our patients showed significant improvement in the morphology of the mac-
ula on OCT scan at one month following their injection. This initial improvement in visual
acuity and CST regressed slightly in the following weeks, but the initial improvement in chro-
matic sensitivity could be demonstrated during week 24.
The almost immediate fluid drying effect of the Ozurdex on the macula with restoration of
anatomical structure can be seen in OCT images. This does not, however, reflect the extent of
damage sustained in the neural retina and can affect some aspects of visual performance such
as the more permanent loss of YB colour vision. In order to assess the full extent of damage
caused by diabetes, the measurement of other visual attributes becomes of interest. Assessment
of chromatic sensitivity changes as shown in this study can have an important role in assessing
the progress of diabetes and the effectiveness of treatment.
DMO is the major contributing factor to loss of sight in DR. It is therefore important to
detect and monitor changes in foveal vision during the course of diabetes. In addition, it is
equally important to be able to detect and monitor how visual performance changes during
the course of treatment so as to be able to assess objectively the effectiveness of treatment.
The findings from this study suggest that RG threshold quantified with the CAD test can be
used to monitor treatment of DMO. At base line all our patients showed loss of RG and YB
thresholds, but post injection with Ozurdex nine out of 14 patients showed significant
improvement in RG thresholds whilst YB colour vision showed little or no improvement.
The current findings are consistent with the outcome of the OCTOME study in relation to
the overall improvement in visual functions post Ozurdex injection. The findings from the
OCTOME study “indicate a positive effect on the retinal neuronal function, probably due to a
realignment of neuronal structures induced by the drying effect of Ozurdex” [12]. The signifi-
cant improvement in RG colour vision observed in this study supports this claim and is consis-
tent with the view that ‘A direct neurotrophic effect of Ozurdex cannot be ruled out‘, provided
the treatment is administered early to avoid permanent damage, as may well be the case with
the less resilient YB system.
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To our knowledge this is the first study to examine the effect of Ozurdex intravitreal injec-
tion on chromatic sensitivity. It may be of great benefit in the future to conduct a similar study
to investigate changes in chromatic sensitivity, contrast sensitivity and rapid flicker in naïve
patients with DMO who are receiving Ozurdex as their first line of treatment. Such a study
may reveal the full functional benefits of Ozurdex treatment and not just the improvement in
BCVA and macular morphology. A new high–sensitivity CAD screener is currently being
developed which will enable individuals to test for both acquired and congenital loss of colour
vision allowing self-monitoring at home.
As per the protocol of the OCTOME study the CAD test was only done once after the injec-
tion, at week 24, but it may be useful in future studies to examine the patients again beyond
week 24 to find out if the observed improvement in RG colour thresholds is sustained.
In conclusion, the major findings from this study reveal significant improvement in RG
colour thresholds post treatment with Ozurdex, with little or no improvement in YB thresh-
olds. Both RG chromatic sensitivity and VA improve post treatment but the percentage
improvements in RG colour vison correlate best with differences in CST “S1 Table”. The find-
ings from this study suggest that in addition to VA and CST, the recovery of RG chromatic
sensitivity can be a useful biomarker in monitoring the efficacy of treatment in DMO.
Supporting information
S1 Table. The data collected for the 14 patients included in the study. It shows data pre and
post injection of intravitreal Dexamethasone implant.
(XLSX)
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